GlassScriptPhysician profile
Lauren Reitmeier
NPI 1972273498
$1,349.44
in general payments reported to CMS, 2019-2025
20 companies · $406 in 2025
The $406 reported for 2025 was more than what 90% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.37 · 2022: $106 · 2023: $347 · 2024: $456 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $526.01 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $110.23 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $106.91 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $79.19 | 2024-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $68.39 | 2022-2025 | Doc Band |
| Sanofi Pasteur INC. | $59.70 | 2023-2025 | |
| Seqirus USA INC | $58.12 | 2024 | Flucelvax |
| Pfizer INC. | $52.95 | 2022-2024 | |
| Krystal Biotech INC | $46.36 | 2023-2024 | Vyjuvek |
| Sanofi-Aventis U.S. LLC | $42.55 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $30.27 | 2025 | Zoryve |
| Alexion Pharmaceuticals, INC. | $24.02 | 2023 | Koselugo |
| Collegium Pharmaceutical, INC. | $23.72 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $22.40 | 2023 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $21.10 | 2024 | Voxzogo 1.2mg |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $16.42 | 2025 | Qelbree |
| Glaxosmithkline, LLC. | $16.06 | 2022 | |
| Neos Therapeutics, LP | $15.68 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.02 | 2025 | |
| Genentech USA, INC. | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Reitmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.